Skip to content
10-K

Annual Report

Akoya Biosciences, Inc.

0001558370-25-003124

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 49.82M sh
Shares Diluted FY 2024 · Dec 31, 2024 49.42M sh
Shares Diluted FY 2024 · Dec 31, 2023 44.43M sh
Capex FY 2024 · Dec 31, 2024 $2.46M
Capex FY 2024 · Dec 31, 2023 $3.65M
Operating Cash Flow FY 2024 · Dec 31, 2024 −$44.1M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$50.9M
Long Term Debt FY 2024 · Dec 31, 2024 $76.18M
Long Term Debt FY 2024 · Dec 31, 2023 $75.25M
Cash And Equivalents FY 2024 · Dec 31, 2024 $11.78M
Cash And Equivalents FY 2024 · Dec 31, 2023 $83.13M
Stockholders Equity FY 2024 · Dec 31, 2024 $7.6M
Stockholders Equity FY 2024 · Dec 31, 2023 $53.77M
Stockholders Equity FY 2024 · Dec 31, 2022 $58.58M
Current Liabilities FY 2024 · Dec 31, 2024 $29.44M
Current Liabilities FY 2024 · Dec 31, 2023 $35.35M
Total Liabilities FY 2024 · Dec 31, 2024 $117.41M
Total Liabilities FY 2024 · Dec 31, 2023 $126.6M
Current Assets FY 2024 · Dec 31, 2024 $76.73M
Current Assets FY 2024 · Dec 31, 2023 $121.79M
Total Assets FY 2024 · Dec 31, 2024 $125.01M
Total Assets FY 2024 · Dec 31, 2023 $180.37M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.12
Eps Diluted FY 2024 · Dec 31, 2023 −$1.43
Eps Basic FY 2024 · Dec 31, 2024 −$1.12
Eps Basic FY 2024 · Dec 31, 2023 −$1.43
Sga Expense FY 2024 · Dec 31, 2024 $69.32M
Sga Expense restated FY 2024 · Dec 31, 2023 $87.36M
Rd Expense FY 2024 · Dec 31, 2024 $19.75M
Rd Expense restated FY 2024 · Dec 31, 2023 $24.97M
Net Income FY 2024 · Dec 31, 2024 −$55.37M
Net Income FY 2024 · Dec 31, 2023 −$63.32M
Operating Income FY 2024 · Dec 31, 2024 −$46.73M
Operating Income FY 2024 · Dec 31, 2023 −$57.67M
Gross Profit FY 2024 · Dec 31, 2024 $47.88M
Gross Profit FY 2024 · Dec 31, 2023 $56.31M
Cost Of Revenue FY 2024 · Dec 31, 2024 $33.79M
Cost Of Revenue FY 2024 · Dec 31, 2023 $40.33M
Revenue FY 2024 · Dec 31, 2024 $81.67M
Revenue FY 2024 · Dec 31, 2023 $96.63M